Keros Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
6analysts covering
FY EPS (est.)
-$5.19next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Third Quarter 2026 Financial Results and Operational Update | 5 Nov 2026 |
| Full Year 2026 Financial Results and Operational Update | 4 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly281.5MTarget: Sufficient to fund operations into the first half of 2028
Quarterly Net Loss Quarterly-23.7MTarget: Minimize cash burn through strategic partnerships and restructuring
Quarterly Research and Development (R&D) Expenses Quarterly16.1MTarget: Maintain disciplined spending following elritercept cost transition to Takeda
Watch Items
- Rinvatercept (KER-065) Phase 2 Trial Initiation in Duchenne Muscular Dystrophy (DMD)Trigger: Initiation of Phase 2 trial in DMDAction: Monitor patient enrollment progress and initial safety/biomarker data readouts expected in 1H 2027
- Elritercept (KER-050) Phase 3 Trial Progress by TakedaTrigger: Takeda advancing elritercept into pivotal Phase 3 trial for anemia in myelofibrosisAction: Track trial initiation, milestone achievements, and future royalty/milestone payment eligibility
- Rinvatercept (KER-065) Regulatory Engagement for ALS Phase 2 DesignTrigger: Regulatory feedback on Phase 2 study design in ALSAction: Evaluate the finalized clinical trial design, patient population, and endpoints in H2 2026
Research as of 19 Jun 2026